Carlos Egea

Carlos Egea

Auto-generated profile, based on publicly available information

Carlos Egea

Bioaraba Health Research Institute, Neuroscience, Sleep Disorders, 01009 Vitoria-Gasteiz, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JMJuan F. Masa
Juan F. Masa
BMBabak Mokhlesi
Babak Mokhlesi
IBIván Benítez
Iván Benítez
MMMaria Victoria Mogollon
Maria Victoria Mogollon
FTFrancisco Javier Gomez de Terreros
Francisco Javier Gomez de Terreros
ONOn Behalf Of The Spanish Sleep Network.
On Behalf Of The Spanish Sleep Network.
Rationale: Obesity hypoventilation syndrome (OHS) has been associated with cardiac dysfunction. However, randomized trials assessing the impact of long-term noninvasive ventilation (NIV) or continuous positive airway pressure (CPAP) on cardiac structure and function assessed by echocardiography are lacking. Objectives: In a prespecified secondary analysis of the largest multicenter randomized controlled trial of OHS (Pickwick Project; N = 221 patients with OHS and coexistent severe obstructive sleep apnea), we compared the effectiveness of three years of NIV and CPAP on structural and functional echocardiographic changes. Methods: At baseline and annually during three sequential years, patients underwent transthoracic two-dimensional and Doppler echocardiography. Echocardiographers at each site were blinded to the treatment allocation. Statistical analysis was performed using a linear mixed-effects model with a treatment group and repeated measures interaction to determine the differential effect between CPAP and NIV. Measurements and Main Results: A total of 196 patients were analyzed: 102 were treated with CPAP and 94 were treated with NIV. Systolic pulmonary artery pressure decreased from 40.5 ± 1.47 mm Hg at baseline to 35.3 ± 1.33 mm Hg at three years with CPAP, and from 41.5 ± 1.56 mm Hg to 35.5 ± 1.42 with NIV (P < 0.0001 for longitudinal intragroup changes for both treatment arms). However, there were no significant differences between groups. NIV and CPAP therapies similarly improved left ventricular diastolic dysfunction and reduced left atrial diameter. Both NIV and CPAP improved respiratory function and dyspnea. Conclusions: In patients with OHS who have concomitant severe obstructive sleep apnea, long-term treatment with NIV and CPAP led to similar degrees of improvement in pulmonary hypertension and left ventricular diastolic dysfunction. Clinical trial registered with www.clinicaltrials.gov (NCT01405976).

3 October 2024 in Journal of Medical Economics
Verified
Journal Article
Open access
FCFrançois-Xavier Chalet
François-Xavier Chalet
EAEmiliano Albanese
Emiliano Albanese
CECarlos Egea
Carlos Egea
JEJason Ellis
Jason Ellis
LSLuigi Ferini Strambi
Luigi Ferini Strambi
AOAbisola Olopoenia
Abisola Olopoenia
Chronic insomnia disorder (CID) is considered a significant worldwide public health concern; however, its exact burden is unknown. We estimate its prevalence across France, Germany, Italy, Spain, and the United Kingdom, and assess the economic and humanistic burden for a broader insomnia population. This retrospective, cross-sectional, observational study used 2020 National Health and Wellness Survey (NHWS) data. Patients reporting insomnia were characterized to define CID. Health-related quality of life (HRQoL), work productivity, and healthcare resource use (HCRU) outcomes were assessed in four cohorts according to insomnia diagnosis and treatment status and examined using multivariable analyses according to Insomnia Severity Index categories. Among 62,319 respondents, 9,035 (21.2%) reported experiencing insomnia over the previous 12 months. CID prevalence rates were 5.5% to 6.7% across the five countries and 6.0% overall. HRQoL outcomes were persistently poorer in cohorts of patients diagnosed with insomnia than those with undiagnosed insomnia. Undiagnosed and treated insomnia patients reported the highest work presenteeism and total work productivity impairment and the highest number of emergency room and hospitalization visits than patients with insomnia (either treated or untreated). After adjusting for covariates, patients with severe insomnia reported significantly worse EQ-5D-5L utility scores, higher absenteeism and presenteeism rates, and more healthcare provider visits over the past 6 months than patients without insomnia (all p < 0.01). Our prevalence rates for CID align with published literature. A diagnosis of insomnia, use of sleep medications, and severity of insomnia are associated with poor quality of life, loss of work productivity, and higher HCRU, confirming the high unmet need and substantial humanistic and economic burden of CID.

26 March 2020 in Thorax
Verified
Journal Article
Closed access
PDF file
JMJuan F Masa
Juan F Masa
BMBabak Mokhlesi
Babak Mokhlesi
IBIván Benítez
Iván Benítez
FCFrancisco Javier Gómez de Terreros Caro
Francisco Javier Gómez de Terreros Caro
MSM-Ángeles Sánchez-Quiroga
M-Ángeles Sánchez-Quiroga
JCJaime Corral-Peñafiel
Jaime Corral-Peñafiel
Background Obesity hypoventilation syndrome (OHS) is treated with either non-invasive ventilation (NIV) or CPAP, but there are no long-term cost-effectiveness studies comparing the two treatment modalities. Objectives We performed a large, multicentre, randomised, open-label controlled study to determine the comparative long-term cost and effectiveness of NIV versus CPAP in patients with OHS with severe obstructive sleep apnoea (OSA) using hospitalisation days as the primary outcome measure. Methods Hospital resource utilisation and within trial costs were evaluated against the difference in effectiveness based on the primary outcome (hospitalisation days/year, transformed and non-transformed in monetary term). Costs and effectiveness were estimated from a log-normal distribution using a Bayesian approach. A secondary analysis by adherence subgroups was performed. Results In total, 363 patients were selected, 215 were randomised and 202 were available for the analysis. The median (IQR) follow-up was 3.01 (2.91–3.14) years for NIV group and 3.00 (2.92–3.17) years for CPAP. The mean (SD) Bayesian estimated hospital days was 2.13 (0.73) for CPAP and 1.89 (0.78) for NIV. The mean (SD) Bayesian estimated cost per patient/year in the NIV arm, excluding hospitalisation costs, was €2075.98 (91.6), which was higher than the cost in the CPAP arm of €1219.06 (52.3); mean difference €857.6 (105.5). CPAP was more cost-effective than NIV (99.5% probability) because longer hospital stay in the CPAP arm was compensated for by its lower costs. Similar findings were observed in the high and low adherence subgroups. Conclusion CPAP is more cost-effective than NIV; therefore, CPAP should be the preferred treatment for patients with OHS with severe OSA. Trial registration number NCT01405976

9 October 2024 in Chest
Verified
Journal Article
Closed access
NNNathan C. Nowalk
Nathan C. Nowalk
BMBabak Mokhlesi
Babak Mokhlesi
JNJulie M. Neborak
Julie M. Neborak
JJJuan Fernando Masa Jimenez
Juan Fernando Masa Jimenez
IBIvan Benitez
Ivan Benitez
MSMaria Ángeles Sánchez-Quiroga
Maria Ángeles Sánchez-Quiroga

12 August 2026 in Clocks & Sleep
Verified
Journal Article
Open access
PDF file
ALAinhoa Alvarez Ruiz de Larrinaga
Ainhoa Alvarez Ruiz de Larrinaga
JUJorge Ullate
Jorge Ullate
AHAlejandro Horrillo-Maysonnial
Alejandro Horrillo-Maysonnial
CPCarla Pía
Carla Pía
CECarlos Egea
Carlos Egea
MSMaria Comas Soberats
Maria Comas Soberats
Background: Obstructive sleep apnea (OSA) has been implicated in declarative memory impairment. Here, we evaluated immediate recall and overnight declarative memory in patients with suspected OSA before and after standard clinical management in a longitudinal cohort of 265 patients. Methods: A nocturnal polysomnographic study (PSG) was performed at baseline and repeated six months later. The Pictorial-Based Declarative Memory Questionnaire (PDMQ) was administered and consisted of four learning trials followed by free-recall 10 min before PSG and the following morning upon awakening. The primary cognitive endpoint was the change in pictorial declarative memory performance from baseline to 6-month follow-up, expressed as the number of correctly recalled items on the PDMQ. Results: Both immediate and delayed recall performances significantly improved in the no OSA/mild OSA and severe OSA groups, whereas only immediate recall improved in the moderate OSA group. In the severe group, comparisons between patients whose apnea–hypopnea index decreased to 30 revealed significant cognitive improvements in both subgroups, particularly in initial and late trials (Trials 1, 2, 5, 6). In multivariable models, baseline PDMQ performance and indices of SpO2 desaturation and sleep fragmentation emerged as independent predictors of change in declarative memory. Conclusions: These findings suggest that routine clinical management of patients with OSA was accompanied by modest, albeit statistically significant improvements in declarative memory, and that both intermittent hypoxia and sleep fragmentation play important roles in memory change.